Gastrointestinal Adverse Events Associated with Tirzepatide: A Pharmacovigilance Analysis
Shen P, Peng MS, Kim SJ, et al.
Summary
A bibliometric and pharmacovigilance analysis of tirzepatide's gastrointestinal side effects, providing real-world safety data from adverse event reporting systems.
Clinical Significance
Helps prescribers understand the real-world GI safety profile of tirzepatide beyond clinical trial data.
Study Overview
This analysis examined gastrointestinal adverse events reported in pharmacovigilance databases for tirzepatide, providing real-world safety data to complement clinical trial findings.
Key Findings
- GI events are the most commonly reported adverse events with tirzepatide
- Nausea, vomiting, and diarrhea are the most frequent complaints
- Most GI events are mild to moderate and improve over time
- Real-world data consistent with clinical trial safety profiles
Clinical Relevance
Real-world pharmacovigilance data helps prescribers counsel patients about expected GI side effects and develop management strategies.
Source
Свързани изследвания
Tirzepatide Reduces Body Weight by 21% in Adults with Obesity: SURMOUNT-1 Trial Results
In a randomized controlled trial of 2,539 adults with obesity, tirzepatide at the highest dose (15mg…
Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: SURPASS-CVOT
In a post hoc analysis of the landmark SURPASS-CVOT trial (n=13,165), tirzepatide demonstrated a 16%…
Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: TOGETHER-PsA Trial
In the TOGETHER-PsA trial (n=271), combining tirzepatide with ixekizumab achieved ACR50 + ≥10% weigh…
Real-World Weight-Loss Outcomes in Weight-Reduced Patients Treated With Tirzepatide
This real-world study of 293 patients found that tirzepatide produced 10.3% total body weight loss i…